Why the study?
Does intravenous immunoglobulin improve symptoms in a patient with HEV-associated Guillain-Barré syndrome presenting with dysgeusia?
Does intravenous immunoglobulin improve symptoms in a patient with HEV-associated Guillain-Barré syndrome presenting with dysgeusia?
This case highlights that HEV-associated Guillain-Barré syndrome may rarely present with dysgeusia, which responds to intravenous immunoglobulin therapy.
Answers are grounded in this paper and cite their sources.
IVIG may improve HEV-associated GBS with dysgeusia; hypothesis-generating and requires confirmation in controlled studies.
Guillain-Barré syndrome (GBS) is usually triggered by viral or bacterial infection. In addition, it was recently reported that infection with hepatitis E virus (HEV) also causes GBS. A 49-year-old man presented with acute-onset paralysis in all extremities and dysgeusia during an episode of acute hepatitis. Serological tests showed the presence of anti-HEV IgM antibodies and HEV-RNA in the serum. As an electrophysiological examination showed acute demyelinating polyradiculoneuropathy, the patient was diagnosed as HEV-associated GBS. Following the initiation of treatment with intravenous immunoglobulin, his paralysis and dysgeusia rapidly improved. This case suggests that HEV-associated GBS may rarely be complicated by dysgeusia.
No takes yet. Share an insight, caveat, or question.
Higuchi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: